DOCSLIB.ORG

Creating Reports and Visualizations to Support Decision Making with the Bizint Smart Charts Product Family

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Patents & IP Sequences | Clinical Trials | Drug Pipelines Creating reports and visualizations to support decision making with the BizInt Smart Charts product family 2019 Analytics & Visualization Meeting, Nice Diane Q. Webb, President 10 April 2019 www.bizint.com takes your search results Patents & IP Sequences | Clinical Trials | Drug Pipelines …and automatically builds tabular reports. Integrating results from different databases. And, helps you create visualizations from your reports. Tables are a powerful tool for visualizing information. Everyone understands how to read a table! Babylonian table (circa 1800 B.C.) Sports results table (circa 2010 A.D.) © 2019 BizInt Solutions, Inc | www.bizint.com 5 Tables are suitable for data sets between a few records and thousands of records (c. 2010) 1 10 100 1k 10k 100k Records Tables Statistics/Visualizations © 2019 BizInt Solutions, Inc | www.bizint.com 6 Standard technical visualizations display aggregate data… © 2019 BizInt Solutions, Inc | www.bizint.com 7 But pharma business visualizations display discrete data… © 2019 BizInt Solutions, Inc | www.bizint.com 8 Tables are suitable for data sets between a few records and thousands of records (c. 2018) 1 10 100 1k 10k 100k Business Visualizations Records Tables Statistics/Visualizations © 2019 BizInt Solutions, Inc | www.bizint.com 9 2013 II-SDV Paper: Challenges in Visualizing Pharmaceutical Business Information The Problem: Visualizations developed for scientific and patent data do not do a good job of “telling the story” when applied to drug pipeline data and often need significant changes. We returned to this topic in 2016 and 2018: bizint.com/slides © 2019 BizInt Solutions, Inc | www.bizint.com 10 Using multiple databases produces better visualizations Because of indexing variation, searches retrieve different results Additional trials returned © 2019 BizInt Solutions, Inc | www.bizint.com 11 Using multiple databases produces better visualizations And there are content variations between databases Missing end date provided by Adis More additional trials returned © 2019 BizInt Solutions, Inc | www.bizint.com 12 But using multiple databases means challenges… 1. Multiple Records for the Same Drug © 2019 BizInt Solutions, Inc | www.bizint.com 13 But using multiple databases means challenges… 2. Conflicting Data for the Same Drug © 2019 BizInt Solutions, Inc | www.bizint.com 14 But using multiple databases means challenges… 3. Terminology Variation © 2019 BizInt Solutions, Inc | www.bizint.com 15 See our “Surfing the Pipeline” papers: bizint.com/slides © 2019 BizInt Solutions, Inc | www.bizint.com 16 One of these challenges is data clean-up.. ! " # $% © 2019 BizInt Solutions, Inc | www.bizint.com 17 One of these challenges is data clean-up.. Vocabulary needs to be normalized. ! " # $% © 2019 BizInt Solutions, Inc | www.bizint.com 18 Event timeline (from clinical trials data) © 2019 BizInt Solutions, Inc | www.bizint.com 19 Piano Chart (from clinical trials data) © 2019 BizInt Solutions, Inc | www.bizint.com 20 Bullseye (created from pipeline data) Small molecules pevonedistat roniciclib LY‐3023414 trametinib porfimer sodium imatinib Marketed sunitinib napabucasin Phase 3 tazemetostat Minerval trabectedin lurbinectedin Phase 2 Cell/Gene therapies dasatinib TRC‐102 nintedanib gemcitabine prodrug Phase 1 vinorelbine defactinib CB‐839 aglatimagene besadenovec gene therapy zoledronic acid carfilzomib MesoCART anti‐mesothelin CAR raltitrexed BNC‐105P AZD‐4547 miR‐15/16 mimics pemetrexed AEOL‐10150 MTG‐201 ONCOS‐102 MTG‐202 MV‐NIS therapy amatuximab HSV‐1716 atezolizumab MV‐NIS ARGX‐110 ipilimumab Oncolytic viruses WT1 vaccine brentuximab vedotin TroVax GL‐ONC1 CAT‐5001 BGB‐A317 nivolumab NGR‐hTNF K562/GM‐CSF durvalumab durvalumab + tremelimumab galinpepimut‐S tremelimumab pegargiminase MesoPher CRS‐207 CK‐301 pembrolizumab YSCMA CBP‐501 JTCR‐016 Cancer vaccines LMB‐100 Antibodies FP‐1039 © 2019 BizInt Solutions, Inc | www.bizint.com Peptides/Proteins 21 Lessons Learned – It’s all about • There is some interest in an interactive visualization that people can explore… • But the primary requirement is for a PowerPoint slide. • An image in a PowerPoint slide is okay… • But you’d really like to create PowerPoint objects (so you can customize the presentation and make final edits.) © 2019 BizInt Solutions, Inc | www.bizint.com 22 “Piano Chart” – PowerPoint visualization Merkel cell carcinoma (MCC) pipeline: Phase for MCC and type of molecule Biological Testing Preclinical Phase I Phase II Launched Discontinued No Development Reported Merkel cell carcinoma CK-301 BGB-A317 ALT 803 avelumab lorvotuzumab mertansine ATN-161 therapies Altor BioScience Corporation ImmunoGen Vironika TG Therapeutics Celgene Merck KGaA Attenuon ETBX-051 ID-G100 cabozantinib S-malate tivantinib NantWorks Immune Design Exelixis ArQule ETBX-061 pasireotide CST-101 NantWorks Novartis NantWorks ipilimumab SIRPa-Fc F16-IL2 Bristol-Myers Squibb Co Trillium Therapeutics Philogen Option for hyperlink LTvax utomilumab MCPyV vaccine Fred Hutchinson Cancer APCure Pfizer Research Center to pipeline record Merkel cell polyomavirus nivolumab inhibitors Vironika Ono Pharmaceutical Co Ltd pazopanib GlaxoSmithKline plc pembrolizumab Merck & Co Each column contains Drugs color-coded by a Type of molecule PEN-221 Antibody the drugs in that phase Tarveda Therapeutics chosen field Biological, other sapanisertib Intellikine Cell & gene therapy Labeled by drug nametalimogene and laherparepvec Protein & peptide BioVex Inc a chosen field Small molecule therapeutic tavokinogene telsaplasmid OncoSec Medical Vaccine © 2019 BizInt Solutions, Inc | www.bizint.com 23 Annotating the Piano Chart in PowerPoint Merkel cell carcinoma (MCC) pipeline: Phase for MCC and type of molecule Biological Testing Preclinical Phase I Phase II Launched Discontinued No Development Reported Merkel cell carcinoma CK-301 BGB-A317 ALT 803 avelumab lorvotuzumab mertansine ATN-161 therapies Altor BioScience Corporation ImmunoGen Vironika TG Therapeutics Celgene Merck KGaA Attenuon ETBX-051 ID-G100 cabozantinib S-malate tivantinib NantWorks Immune Design Exelixis ArQule ETBX-061 pasireotide CST-101 NantWorks Novartis NantWorks ipilimumab SIRPa-Fc F16-IL2 Bristol-Myers Squibb Co Trillium Therapeutics Philogen LTvax utomilumab MCPyV vaccine Fred Hutchinson Cancer Add box outlines to APCure Pfizer Research Center Merkel cell polyomavirus nivolumab inhibitors indicate Key Competitors Vironika Ono Pharmaceutical Co Ltd pazopanib GlaxoSmithKline plc pembrolizumab Merck & Co Type of molecule PEN-221 Key Competitor Antibody Tarveda Therapeutics Biological, other sapanisertib Intellikine Cell & gene therapy talimogene laherparepvec Protein & peptide BioVex Inc Small molecule therapeutic tavokinogene telsaplasmid OncoSec Medical Vaccine © 2019 BizInt Solutions, Inc | www.bizint.com 24 Annotating the Piano Chart in PowerPoint Merkel cell carcinoma (MCC) pipeline: Phase for MCC and type of molecule Biological Testing Preclinical Phase I Phase II Launched Discontinued No Development Reported Merkel cell carcinoma CK-301 BGB-A317 ALT 803 avelumab lorvotuzumab mertansine ATN-161 therapies Altor BioScience Corporation ImmunoGen Vironika TG Therapeutics Celgene Merck KGaA Attenuon ETBX-051 ID-G100 cabozantinib S-malate tivantinib NantWorks Immune Design Exelixis ArQule ETBX-061 pasireotide CST-101 NantWorks Novartis NantWorks ipilimumab SIRPa-Fc F16-IL2 Bristol-Myers Squibb Co Trillium Therapeutics Philogen LTvax utomilumab MCPyV vaccine Fred Hutchinson Cancer Another way to indicate APCure Pfizer Research Center Merkel cell polyomavirus nivolumab inhibitors Key Competitors Vironika Ono Pharmaceutical Co Ltd pazopanib GlaxoSmithKline plc pembrolizumab Merck & Co Type of molecule PEN-221 Key Competitor Antibody Tarveda Therapeutics Biological, other sapanisertib Intellikine Cell & gene therapy talimogene laherparepvec Protein & peptide BioVex Inc Small molecule therapeutic tavokinogene telsaplasmid OncoSec Medical Vaccine © 2019 BizInt Solutions, Inc | www.bizint.com 25 Lessons Learned – It’s not “Easy” • Everyone wants an “easy” button! • We’ve made the actual drawing of the visualizations easy. • But a lot of data preparation is necessary -- • Filter large datasets to the most critical items • Group values to create useful categories. • Shorten labels to fit. • Apply expertise for values not in the data. © 2019 BizInt Solutions, Inc | www.bizint.com 26 Data Preparation for a drug Launch Timeline Group items into a few categories Launch Date is not a field in the data! Group items into a few colors. © 2019 BizInt Solutions, Inc | www.bizint.com 27 Piano Chart without data preparation Piano Chart - Mesothelioma Phase 1 Phase 1/2 Phase 2 Phase 3 Preregistration Launched AEOL-10150 JTCR‐016 aglatimagene besadenovec ipilimumab pemetrexed Pemetrexed ‐ CJ Healthcare AEOL‐10150 JTCR‐016 aglatimagene besadenovec ipilimumab pemetrexed pemetrexed disodium AEOL‐10150 JTCR‐016 aglatimagene besadenovec ipilimumab pemetrexed pemetrexed disodium allogeneic tumor lysate‐pulsed autologous dendritic cells JTCR‐016 amatuximab ipilimumab pemetrexed disodium allogeneic tumor lysate‐pulsed autologous dendritic cells JTCR‐016 amatuximab ipilimumab pemetrexed disodium allogeneic tumor lysate‐pulsed autologous dendritic cells pevonedistat amatuximab ipilimumab pemetrexed disodium allogeneic tumor lysate‐pulsed autologous dendritic cells pevonedistat amatuximab ipilimumab raltitrexed allogeneic tumor lysate‐pulsed autologous
Recommended publications
  • Antibody Drug Conjugate Development in Gastrointestinal Cancers: Hopes and Hurdles from Clinical Trials

    Antibody Drug Conjugate Development in Gastrointestinal Cancers: Hopes and Hurdles from Clinical Trials

    Wu et al. Cancer Drug Resist 2018;1:204-18 Cancer DOI: 10.20517/cdr.2018.16 Drug Resistance Review Open Access Antibody drug conjugate development in gastrointestinal cancers: hopes and hurdles from clinical trials Xiaorong Wu, Thomas Kilpatrick, Ian Chau Department of Medical oncology, Royal Marsden Hospital NHS foundation trust, Sutton SM2 5PT, UK. Correspondence to: Dr. Ian Chau, Department of Medical Oncology, Royal Marsden Hospital NHS foundation trust, Downs Road, Sutton SM2 5PT, UK. E-mail: [email protected] How to cite this article: Wu X, Kilpatrick T, Chau I. Antibody drug conjugate development in gastrointestinal cancers: hopes and hurdles from clinical trials. Cancer Drug Resist 2018;1:204-18. http://dx.doi.org/10.20517/cdr.2018.16 Received: 31 Aug 2018 First Decision: 8 Oct 2018 Revised: 13 Nov 2018 Accepted: 16 Nov 2018 Published: 19 Dec 2018 Science Editors: Elisa Giovannetti, Jose A. Rodriguez Copy Editor: Cui Yu Production Editor: Huan-Liang Wu Abstract Gastrointestinal (GI) cancers represent the leading cause of cancer-related mortality worldwide. Antibody drug conjugates (ADCs) are a rapidly growing new class of anti-cancer agents which may improve GI cancer patient survival. ADCs combine tumour-antigen specific antibodies with cytotoxic drugs to deliver tumour cell specific chemotherapy. Currently, only two ADCs [brentuximab vedotin and trastuzumab emtansine (T-DM1)] have been Food and Drug Administration approved for the treatment of lymphoma and metastatic breast cancer, respectively. Clinical research evaluating ADCs in GI cancers has shown limited success. In this review, we will retrace the relevant clinical trials investigating ADCs in GI cancers, especially ADCs targeting human epidermal growth receptor 2, mesothelin, guanylyl cyclase C, carcinogenic antigen-related cell adhesion molecule 5 (also known as CEACAM5) and other GI malignancy specific targets.
  • Preclinical Efficacy of an Antibody–Drug Conjugate Targeting

    Preclinical Efficacy of an Antibody–Drug Conjugate Targeting

    Published OnlineFirst October 19, 2016; DOI: 10.1158/1535-7163.MCT-16-0449 Large Molecule Therapeutics Molecular Cancer Therapeutics Preclinical Efficacy of an Antibody–Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET Anton G.T. Terwisscha van Scheltinga1,2, Annie Ogasawara1, Glenn Pacheco1, Alexander N. Vanderbilt1, Jeff N. Tinianow1, Nidhi Gupta1, Dongwei Li1, Ron Firestein1, Jan Marik1, Suzie J. Scales1, and Simon-Peter Williams1 Abstract Antibody–drug conjugates (ADC) use monoclonal antibo- and HPAF-II, or mesothelioma MSTO-211H. Ex vivo analysis dies (mAb) as vehicles to deliver potent cytotoxic drugs selec- of mesothelin expression was performed using immunohis- tively to tumor cells expressing the target. Molecular imaging tochemistry. AMA-MMAE showed the greatest growth inhibi- with zirconium-89 (89Zr)-labeled mAbs recapitulates similar tion in OVCAR-3Â2.1, Capan-2, and HPAC tumors, which targeting biology and might help predict the efficacy of these showed target-specific tumor uptake of 89Zr-AMA. The less ADCs. An anti-mesothelin antibody (AMA, MMOT0530A) was responsive xenografts (AsPC-1, HPAF-II, and MSTO-211H) did used to make comparisons between its efficacy as an ADC and not show 89Zr-AMA uptake despite confirmed mesothelin its tumor uptake as measured by 89Zr immunoPET imaging. expression. ImmunoPET can demonstrate the necessary deliv- Mesothelin-targeted tumor growth inhibition by monomethyl ery, binding, and internalization of an ADC antibody in vivo auristatin E (MMAE), ADC AMA-MMAE (DMOT4039A), andthiscorrelateswiththeefficacy of mesothelin-targeted ADC was measured in mice bearing xenografts of ovarian cancer in tumors vulnerable to the cytotoxic drug delivered. Mol Cancer OVCAR-3Â2.1, pancreatic cancers Capan-2, HPAC, AsPC-1, Ther; 16(1); 134–42.
  • PHOTOSTENT-02: Porfimer Sodium Photodynamic Therapy Plus Stenting Versus Stenting Alone in Patients with Locally Advanced Or Metastatic Biliary Tract Cancer

    PHOTOSTENT-02: Porfimer Sodium Photodynamic Therapy Plus Stenting Versus Stenting Alone in Patients with Locally Advanced Or Metastatic Biliary Tract Cancer

    Open access Original research ESMO Open: first published as 10.1136/esmoopen-2018-000379 on 23 July 2018. Downloaded from PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer Stephen P Pereira,1,2 Mark Jitlal,3 Marian Duggan,3 Emma Lawrie,3 Sandy Beare,3 Pam O'Donoghue,4 Harpreet S Wasan,5 Juan W Valle,6 John Bridgewater,7 on behalf of the PHOTOSTENT-02 investigators To cite: Pereira SP, ABSTRACT Key questions Jitlal M, Duggan M, et al. Background Endobiliary stenting is standard practice for PHOTOSTENT-02: porfimer palliation of obstructive jaundice due to biliary tract cancer sodium photodynamic therapy What is already known about this subject? (BTC). Photodynamic therapy (PDT) may also improve plus stenting versus stenting In patients with obstructive jaundice due to unre- biliary drainage and previous small studies suggested ► alone in patients with locally sectable cholangiocarcinoma, small studies have survival benefit. advanced or metastatic biliary suggested that photodynamic therapy (PDT) may Aims To assess the difference in outcome between tract cancer. ESMO Open improve biliary drainage and patient survival. 2018;3:e000379. doi:10.1136/ patients with BTC undergoing palliative stenting plus PDT esmoopen-2018-000379 versus stenting alone. What does this study add? Methods 92 patients with confirmed locally advanced ► We conducted a large randomised controlled trial or metastatic BTC, ECOG performance status 0–3 and of porfimer sodium PDT in patients with confirmed JWV and JB contributed equally. adequate biliary drainage were randomised (46 per locally advanced or metastatic biliary tract cancer.
  • Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy

    Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy

    cancers Review Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy Laura Boyero 1 , Amparo Sánchez-Gastaldo 2, Miriam Alonso 2, 1 1,2,3, , 1,2, , José Francisco Noguera-Uclés , Sonia Molina-Pinelo * y and Reyes Bernabé-Caro * y 1 Institute of Biomedicine of Seville (IBiS) (HUVR, CSIC, Universidad de Sevilla), 41013 Seville, Spain; [email protected] (L.B.); [email protected] (J.F.N.-U.) 2 Medical Oncology Department, Hospital Universitario Virgen del Rocio, 41013 Seville, Spain; [email protected] (A.S.-G.); [email protected] (M.A.) 3 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain * Correspondence: [email protected] (S.M.-P.); [email protected] (R.B.-C.) These authors contributed equally to this work. y Received: 16 November 2020; Accepted: 9 December 2020; Published: 11 December 2020 Simple Summary: Immuno-oncology has redefined the treatment of lung cancer, with the ultimate goal being the reactivation of the anti-tumor immune response. This has led to the development of several therapeutic strategies focused in this direction. However, a high percentage of lung cancer patients do not respond to these therapies or their responses are transient. Here, we summarized the impact of immunotherapy on lung cancer patients in the latest clinical trials conducted on this disease. As well as the mechanisms of primary and acquired resistance to immunotherapy in this disease. Abstract: After several decades without maintained responses or long-term survival of patients with lung cancer, novel therapies have emerged as a hopeful milestone in this research field.
  • Exhibit #4 Outpatient Surgery Facility Codes and Fees Source: 2019 CN2 Addendum A.12212018 Effective 1/1/2020

    Exhibit #4 Outpatient Surgery Facility Codes and Fees Source: 2019 CN2 Addendum A.12212018 Effective 1/1/2020

    Exhibit #4 Outpatient Surgery Facility Codes and Fees source: 2019 CN2 Addendum A.12212018 Effective 1/1/2020 APC Short Descriptor Outpatient ASC Rate Additional Hospital Rate (85% of Instructions (180% of Hospital Rate) Medicare $) 0701 Sr89 strontium $ 2,704.24 $ 2,298.60 0726 Dexrazoxane HCl injection $ 413.87 $ 351.79 0731 Sargramostim injection $ 67.69 $ 57.54 0736 Amphotericin b liposome inj $ 86.52 $ 73.54 0738 Rasburicase $ 500.66 $ 425.56 0751 Mechlorethamine hcl inj $ 579.10 $ 492.24 0752 Dactinomycin injection $ 2,569.80 $ 2,184.33 0759 Naltrexone, depot form $ 5.86 $ 4.98 0800 Leuprolide acetate $ 2,148.60 $ 1,826.31 0802 Etoposide oral $ 136.01 $ 115.61 0807 Aldesleukin injection $ 7,448.66 $ 6,331.36 0809 Bcg live intravesical vac $ 253.11 $ 215.14 0810 Goserelin acetate implant $ 916.24 $ 778.80 0812 Carmustine injection $ 7,292.71 $ 6,198.80 0820 Daunorubicin injection $ 91.19 $ 77.51 0823 Docetaxel injection $ 2.72 $ 2.31 0825 Nelarabine injection $ 273.99 $ 232.89 0836 Interferon alfa-2b inj $ 61.46 $ 52.24 0840 Inj melphalan hydrochl $ 1,466.65 $ 1,246.65 0843 Pegaspargase injection $ 27,051.68 $ 22,993.93 0844 Pentostatin injection $ 3,773.31 $ 3,207.31 0850 Streptozocin injection $ 627.67 $ 533.52 0851 Thiotepa injection $ 1,334.84 $ 1,134.61 0856 Porfimer sodium injection $ 38,195.22 $ 32,465.94 0858 Inj cladribine $ 40.75 $ 34.64 0864 Mitoxantrone hydrochl $ 49.25 $ 41.86 0873 Hyalgan supartz visco-3 dose $ 153.55 $ 130.52 0874 Synvisc or synvisc-one $ 21.29 $ 18.10 0875 Euflexxa inj per dose $ 254.65 $ 216.45 0877
  • 2017 Immuno-Oncology Medicines in Development

    2017 Immuno-Oncology Medicines in Development

    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
  • Oregon Health Authority Division of Medical Assistance Programs Addendum a - Final OPPS Apcs for CY 2012 Effective October 1, 2012

    Oregon Health Authority Division of Medical Assistance Programs Addendum a - Final OPPS Apcs for CY 2012 Effective October 1, 2012

    Oregon Health Authority Division of Medical Assistance Programs Addendum A - Final OPPS APCs for CY 2012 Effective October 1, 2012 Relative APC Group Title SI Weight 0001 Level I Photochemotherapy S 0.5042 0002 Fine Needle Biopsy/Aspiration T 1.6115 0003 Bone Marrow Biopsy/Aspiration T 3.5702 0004 Level I Needle Biopsy/ Aspiration Except Bone Marrow T 4.5746 0005 Level II Needle Biopsy/Aspiration Except Bone Marrow T 8.1566 0006 Level I Incision & Drainage T 1.4206 0007 Level II Incision & Drainage T 13.1250 0008 Level III Incision and Drainage T 20.5648 0012 Level I Debridement & Destruction T 0.3878 0013 Level II Debridement & Destruction T 0.8785 0015 Level III Debridement & Destruction T 1.4989 0016 Level IV Debridement & Destruction T 2.7592 0017 Level V Debridement & Destruction T 21.6661 0019 Level I Excision/ Biopsy T 4.4238 0020 Level II Excision/ Biopsy T 8.2746 0021 Level III Excision/ Biopsy T 17.0074 0022 Level IV Excision/ Biopsy T 23.2662 0028 Level I Breast Surgery T 25.5054 0029 Level II Breast Surgery T 33.4070 0030 Level III Breast Surgery T 44.8999 0031 Smoking Cessation Services X 0.2997 0034 Mental Health Services Composite S 2.7295 0035 Vascular Puncture and Minor Diagnostic Procedures X 0.2691 0037 Level IV Needle Biopsy/Aspiration Except Bone Marrow T 15.3499 0039 Level I Implantation of Neurostimulator Generator S 216.7598 0040 Level I Implantation/Revision/Replacement of Neurostimulator Electrodes S 63.7616 0041 Level I Arthroscopy T 29.6568 0042 Level II Arthroscopy T 57.0137 0045 Bone/Joint Manipulation Under
  • The Two Tontti Tudiul Lui Hi Ha Unit

    The Two Tontti Tudiul Lui Hi Ha Unit

    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
  • Original New Drug Applications

    Original New Drug Applications

    New Drugs Reviewed by CPG January 23, 2017 (Original New Drug Applications: FDA) Generic Name Trade Name Indication(s) CPG Action Immune globulin Cuvitru Biologic and In accordance with subcutaneous Immunological the SCA [human] 20% solution Agents/Immune Globulins/ Immune Globulin (Human) subcutaneous. Indicated as replacement for primary humoral immunodeficiency in adult and pediatric patients age two and older. eteplirsen Exondys 51 Central Nervous System In accordance with Agents/Antisense the SCA Oligonucleotides. Treatment of patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping. First drug approved for reatment of patients with Duchenne muscular dystrophy. levonorgestrel- Kyleena Endocrine and May prescribe releasing intrauterine Metabolic Agents/sex system 19.5 mg homones/contraceptive Hormones. Prevention of pregnancy for up to five years. **Phentermine Lomaira Central Nervous System In accordance with hydrochloride 8 mg Agents/ the SCA anorexiants/sympathomi metic anorexiants. Short term use weight reduction in adults with **(new formulation at an initial BMI of 30 or lower dosage) more or 27 with at least one weight-related condition. 1 New Drugs January 2017 canaglifozin/ Invokamet XR Endocrine and May prescribe metformin HCL Metabolic Agents/ extended-release antidiabetic agents/antidiabetic combination products. Treatment of adults with type 2 diabetes as an adjunct to diet and exercise. Adalimumab-atto Amjevita Biologic and In accordance with Immunological Agents/ the SCA Immunologic Agents/Immunomodulat ors/Tumor necrosis Factor-Alpha Blockers. Indicated for treatment of adults with: rheumatoid arthritis, psoriatic arthritis,ankylosing spondylitis, Crohn disease, ulcerative colitis, and plaque psoriasis. Also indicated for juvenile idiopathic arthritis in pts age 4 years and older.
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub

    (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub

    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
  • Targeting and Efficacy of Novel Mab806-Antibody-Drug Conjugates in Malignant Mesothelioma

    Targeting and Efficacy of Novel Mab806-Antibody-Drug Conjugates in Malignant Mesothelioma

    pharmaceuticals Article Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma 1,2,3, 1,3,4, 5 5 Puey-Ling Chia y, Sagun Parakh y, Ming-Sound Tsao , Nhu-An Pham , Hui K. Gan 1,2,3,4, Diana Cao 1, Ingrid J. G. Burvenich 1,2 , Angela Rigopoulos 1, Edward B. Reilly 6, Thomas John 1,2,3,4,* and Andrew M. Scott 1,2,4,7,* 1 Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Victoria 3084, Australia; [email protected] (P.-L.C.); [email protected] (S.P.); [email protected] (H.K.G.); [email protected] (D.C.); [email protected] (I.J.G.B.); [email protected] (A.R.) 2 Faculty of Medicine, University of Melbourne, Melbourne, Victoria 3010, Australia 3 Department of Medical Oncology, Austin Health, Melbourne, Victoria 3084, Australia 4 School of Cancer Medicine, La Trobe University, Plenty Rd &, Kingsbury Dr, Bundoora, Victoria 3086, Australia 5 Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada; [email protected] (M.-S.T.); [email protected] (N.-A.P.) 6 AbbVie Inc., North Chicago, IL 60064, USA; [email protected] 7 Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Victoria 3084, Australia * Correspondence: [email protected] (T.J.); [email protected] (A.M.S.); Tel.: +61-39496-5876 (A.M.S.); Fax: +61-39496-5334 (A.M.S.) These authors contributed equally to this work. y Received: 7 September 2020; Accepted: 28 September 2020; Published: 2 October 2020 Abstract: Epidermal growth factor receptor (EGFR) is highly overexpressed in malignant mesothelioma (MM).
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T

    WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).